Oppenheimer Reiterates Outperform on Harmony Biosciences, Raises Price Target to $59
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Francois Brisebois has reiterated an Outperform rating on Harmony Biosciences and raised the price target from $56 to $59.
October 30, 2024 | 3:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has reiterated its Outperform rating on Harmony Biosciences and increased the price target from $56 to $59, indicating a positive outlook.
The reiteration of an Outperform rating and an increased price target by a reputable analyst can boost investor confidence, potentially leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100